MGUS and multiple myeloma awareness screening study
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study screens adults aged 40 and older for early signs of MGUS (a benign blood condition) and multiple myeloma (a blood cancer). You'll fill out questionnaires about your health to help with early detection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years old or older.
- You are willing to review and sign a consent form.
- You can fill out questionnaires on your own or with help.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial screens first-degree relatives of people with multiple myeloma to check for early signs of the disease before symptoms. It may help doctors understand risk in families and find problems sooner if they occur.
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This trial is screening for a condition called monoclonal gammopathy (abnormal proteins in the blood) using a new testing method. It is for people who are already having certain blood tests as part of their medical care or routine checkup.
Hear when a new Monoclonal Gammopathy of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.